Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical comparability of semaglutide drug products (process J vs process B) in type 2 diabetes
2021-001501-69Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to week 28. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-001501-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001501-69.